BUSINESS
DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
Dainippon Sumitomo Pharma’s (DSP) sales during the April-September period climbed 1.5% from the same period last year to 181,396 million yen, helped by increased sales in North America of its atypical antipsychotic drug Latuda (lurasidone HCl). However, DSP said its…
To read the full story
BUSINESS
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
- Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan
December 9, 2025
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





